about
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerRenal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.Cytochrome P450 and ischemic heart disease: current concepts and future directions.Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.Targeted arginine metabolomics: A rapid, simple UPLC-QToF-MS(E) based approach for assessing the involvement of arginine metabolism in human disease.Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes.Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters.The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9.Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.Response to in vitro and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin.Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.Plasma extracellular nanovesicle (exosome) derived biomarkers for drug metabolism pathways: A novel approach to characterise variability in drug exposureBinding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolationApplication of the fluorescent probe 1-anilinonaphthalene-8-sulfonate to the measurement of the nonspecific binding of drugs to human liver microsomesTransporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition
P50
Q27027648-53B4C9A3-114D-4210-9080-DFDE4F9595C3Q34325249-E684298F-FC6E-4623-9111-29C13E2ECFFFQ38107524-0071D1BF-F10E-4360-A8D4-67D28C9AFD90Q38166022-71212721-7CEA-476C-BDA0-88370114B2F8Q38239192-0821E8B0-5AF1-409D-A2BB-CFF3315C3D38Q38254564-16E1ACA1-F7A1-4911-A99B-63F201C618F1Q39999160-7B4060D8-1581-4D64-873A-2595F1E2BB92Q40887486-69252121-EE83-4A9E-B6FC-3DD4E47928CBQ41764396-AAD7819C-5B7C-42DB-94AD-76499C7F6C02Q45403198-B5BBCC98-16F9-4ECA-9F84-D9F4B0ADD751Q46767777-17BC6114-910F-4108-B55F-DDDEF9F54B00Q47384439-9ABECA06-387B-4AC0-BFB5-9A6DB01F14B6Q47409686-A51C2600-C3C2-43E6-9299-6047702F4575Q47842968-9DFB6E25-036A-400B-9CBD-CDF2DC7DF03CQ47853973-F649718A-4242-4D3F-B237-886EAE9EFA62Q48370315-D16B080A-DA07-49A9-AC26-399B1D46B0FAQ52637929-B7E059EA-8425-41F8-BC41-CBAB484976A2Q58586562-AB978CF0-3672-4268-A36A-D0A00D8A8557Q79609080-F62A2333-94CB-493F-B3E4-F0C7AA3E99F7Q84189642-93FD9348-22E6-42AB-AA31-9510A572DE2CQ85930608-2C9F9329-9D46-4C37-B858-B11114DA3511
P50
description
researcher (ORCID 0000-0002-8946-3954)
@en
name
Andrew Rowland
@en
Andrew Rowland
@nl
type
label
Andrew Rowland
@en
Andrew Rowland
@nl
prefLabel
Andrew Rowland
@en
Andrew Rowland
@nl
P31
P496
0000-0002-8946-3954